ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib

Sorafenib is the only approved drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its efficacy is limited by the emergence of primary and/or acquired resistance. Senescence-associated secretory phenotype (SASP)-mediated chemo-resistance, which depends on the secreted bioacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Lei-lei, Cheng, Chuan-le, Li, Ming-Yue, Yang, Sheng-li, Hu, Bao-guang, Chong, Charing C. N., Chan, Stephen L., Ren, Jianwei, Chen, George G., Lai, Paul B. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113298/
https://www.ncbi.nlm.nih.gov/pubmed/30154433
http://dx.doi.org/10.1038/s41419-018-0926-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113298/
https://www.ncbi.nlm.nih.gov/pubmed/30154433
http://dx.doi.org/10.1038/s41419-018-0926-x

Ejemplares similares